Top commercial considerations for leaders securing early-stage investment in FY 26-27
In this guest blog, Lee Smith, Managing Partner of GreyRigge Associates, and Spiros Servos, Senior Commercial Consultant at GreyRigge Associates, argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors. From building a commercially informed Target Product Profile to stress-testing value, tracking competition and designing trials with reimbursement in mind, early commercial rigour directly strengthens valuation and deal leverage.
Commercial strategy isn't something you bolt on before launch. For early-stage biotech CEOs, it's the engine behind every major decision, and investors in 2026 know the difference.
Too many promising companies arrive at Series A or B having treated commercialisation as a future task. By that point, the window to shape both the science and the strategy in tandem has often closed. The companies consistently attracting capital today demonstrate not just scientific rigour, but an early credible commercial narrative.
Here are the five crucial considerations to involve in your strategy.
- Build your Target Product Profile like a strategist, not a scientist
The Target Product Profile (TPP) is widely misunderstood as a technical document. A well-constructed TPP articulates your clinical, regulatory outcomes, as well as commercial, into a single coherent picture that speaks to not just physicians, but payers and investors. The extra consideration of commercial outcomes, and payers and investors as an audience makes this seemingly technical document a strategic one instead when made with this approach. A Phase 1 immunotherapy start-up used exactly this approach to secure a £160 million licensing deal by demonstrating commercially informed endpoints alongside early safety signals.
- Model your value. Then stress-test it
Risk-adjusted Net Present Value (rNPV) analysis gives credibility to your asset's potential, but the model is only as credible as its assumptions. Misjudged pricing benchmarks or gaps in competitive intelligence will be probed during due diligence. One neurology biotech used disciplined rNPV modelling to deprioritise a secondary indication consuming focus without proportional return and clearing the path to a closed £80 million Series A.
- Treat the competitive landscape as a living document
A one-time glance at the competition is not market intelligence. Trial readouts shift, pipelines evolve and new entrants emerge. Companies that track this continuously avoid being caught off-guard. One team discovered mid-development that a rival's pivotal readout was just two quarters away. Starting an ongoing review earlier would have made for a far less costly pivot.
- Design your clinical strategy with reimbursement in mind
Health Technology Assessment agencies are a stakeholder from day one, not an afterthought. Endpoints that demonstrate genuine patient and system value carry far more weight than those optimised purely for regulatory approval. One rare disease company incorporated an active-comparator arm based on early payer feedback, achieved conditional reimbursement and reached market nine months ahead of schedule.
- Know your position before you enter any deal room
Commercial preparation directly improves negotiating leverage, regardless of the goal being licensing, co-development or acquisition. A clearly modelled rNPV and well-defined TPP are the difference between defending your valuation and accepting the first number on the table. One oncology company mapped its programme against gaps in a top ten pharma pipeline and secured a co-development agreement as a result.
The science has to be there, but in 2026, that's the baseline. What secures the term sheet is the ability to demonstrate where your product fits, who will pay for it and why it matters, backed by evidence rather than aspiration.
This is a guest blog. Its author is responsible for content within it, which does not necessarily reflect the opinions or positions of BIA.
